Integrated Report

Overview

The report describes Sawai Pharmaceutical's transition to Sawai Group Holdings on April 1, 2021, establishing a new group structure and sustainability committee. It reports FY2020 consolidated revenue of ¥187,219 million despite the COVID-19 pandemic and highlights the generic-drug business's contribution to healthcare-cost reduction. The report also sets a 25% cut in CO2 emissions on a production-volume intensity basis by FY2030 and links healthcare, diversity, climate, and governance priorities to specific Sustainable Development Goals.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2020
Period: 1 April 2020 – 31 March 2021
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services